BioSpace News Archive

International medical imaging IT and cybersecurity company Sectra has significant variations in financial outcomes between periods and its earnings have traditionally been low during the first quarter of the year.

Certara, Inc., a global leader in biosimulation, announced a proposed underwritten public offering of 20,000,000 shares of its common stock pursuant to a registration statement filed with the Securities and Exchange Commission.

Phio Pharmaceuticals Corp., a biotechnology company developing the next generation of immuno-oncology therapeutics based on its proprietary self-delivering RNAi therapeutic platform, announced that it will participate in the H.C. Wainwright 23rd Annual Global Investment Conference, which is being held virtually from September 13 to 15, 2021.

Ginkgo Bioworks Inc., which is building the leading horizontal platform for cell programming and recently announced a business combination with Soaring Eagle Acquisition Corp., announced that management is scheduled to participate in the following upcoming conferences

Amicus Therapeutics announced that members of the Amicus senior leadership team will participate in upcoming presentations at the following virtual investor conferences in September:

Concert Pharmaceuticals, Inc. announced that it will participate virtually at the following upcoming investor conferences.

ADC Therapeutics SA (NYSE: ADCT), announced today that Jay Feingold, MD, PhD, Senior Vice President and Chief Medical Officer, will depart the company to pursue a new opportunity

G1 Therapeutics, Inc., a commercial-stage oncology company, announced that the Company will participate in two upcoming virtual investor conferences in September.

IMMUNOPRECISE ANTIBODIES LTD. (the “Company” or “IPA”) (NASDAQ: IPA) (TSX VENTURE: IPA) a leader in full-service, therapeutic antibody discovery and development, today announced that it will host a conference call to discuss its financial results and recent business highlights for first quarter fiscal year 2022, on September 9, 2021, after the close of market.

Pacific Biosciences of California, Inc. announced that its executives will be speaking at the following investor conferences.